Eli Lilly shares first human trial results for LOXO-435, a selective FGFR3 inhibitor for bladder cancer, showing 41% response ...

Genescience Pharmaceuticals Co. Ltd. has prepared and tested new fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

The study will assess the efficacy and safety of TYRA-300, an oral, selective FGFR3 inhibitor designed to target the FGFR3 gene mutation commonly seen in NMIBC, while avoiding the toxicities ...

“FGFR3 appears to be particularly important ... who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. The phase 3 THOR trial was presented at the 2023 American ...

Overexpression of fibroblast growth factor receptor 3 (FGFR3) has been shown to drive oncogenesis in a subset of patients with multiple myeloma. However, epithelial cancers — such as bladder ...

Tasurgratinib (also known as E-7090) is an oral selective FGFR1, FGFR2, and FGFR3 inhibitor that, if approved, will join other drugs in the class on the market, including Incyte’s Pemazyre ...

TYRA-300 is a potential first-in-class, investigational, oral, FGFR3-selective inhibitor designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic ...

The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of ...

The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of ...